AHA Redefines Triglyceride Target as 100 mg/dL
May 1, 2011|Clinical Endocrinology News
Author and Disclosure Information
From Circulation
Perhaps the high prevalence of hypertriglyceridemia in patients with the metabolic syndrome accounts for the intensity of these recommendations, in which case I applaud this attempt.
ANTONIO M. GOTTO JR., M.D., is the dean of Weill Cornell Medical College, New York. He is a consultant for AstraZeneca, KOWA, and Merck; is on the Board of Directors for Aegerion Pharmaceuticals and Arisaph Pharmaceuticals; and is on advisory boards for DuPont and Vatera Capital.
Document
Vitals
